A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

C

Chong Kun Dang

Status and phase

Completed
Phase 1

Conditions

Dyslipidemias

Treatments

Drug: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)
Drug: Test drug(CKD-337)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03346187
146BE16007

Details and patient eligibility

About

A randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetic characteristics of CKD-337 in healthy male volunteers

Full description

This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetics of CKD-337 in healthy male volunteers. Subjects will receive either a single oral dose of the test formulation(CKD-337) or a oral dose of the reference formulation(Atorvastatin Calcium Trihydrate+Fenofibrate). Each treatment period was separated by a washout period of at least 7 days.

Enrollment

60 patients

Sex

Male

Ages

19 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy male older than 19 years and under 45 years at the time of screening

BMI 17.5~30.5 kg/m² and body weight more than 55kg

  • BMI = Weight(kg)/{Height(m)}²
  • Subject who is no chronic disease, no symptoms or pathological findings
  • Suitable subject who is determined by laboratory tests(hematology test, blood chemistry, urinalysis test etc.), Vital Sign, ECG test at the time of screening
  • Subject who fully understand the clinical trials after in-depth explanation, decide to join the clinical trials and sign on an inform consent from willing

Exclusion criteria

Subject who has a clinically significant disease such as hepatic, kidneys, neurological, respiratory, endocrine, hemato-oncology, urinary, cardiovascular, musculoskeletal or psychiatric diseases and who has a following history

  • Gallbladder disease including cholelithiasis, severe hepatic impairment
  • Acute/chronic pancreatitis due to hypertriglyceridemia
  • Pulmonary embolism or interstitial lung disease
  • Genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
  • Hypoalbuminemia
  • Alcoholics
  • Predisposition to rhabdomyolysis
  • Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption
  • Subject who has hypersensitivity to the drug composition containing choline fenofibrate, fenofibrate or atorvastatin, and other drug(aspirin, fenofibrate series, antibiotic and so on)

The following clinical significant findings in the EKG at the time of screening

  • QTc(Q-T interval corrected for heart rate) > 450ms
  • PR interval(The interval between the beginning of the P wave and the beginning of the QRS complex in ECG) > 200msec
  • QRS duration(The duration of the Q,R and S wave in ECG) > 120msec

The following results in the clinical laboratory tests

  • CPK(Creatinine Phospho-Kinase) > 2 x upper limit of normal range
  • Liver function test(AST; Aspartate Transaminase, ALT; Alanine Transaminase, ALP; Alkaline phosphatase, Total bilirubin, γ-GT) > 2 x upper limit of normal range
  • eGFR(Estimated Glomerular Filtration Rate) < 60 mL/min/1.73m² Calculated by MDRD(Modification of Diet in Renal Disease)
  • Systolic blood pressure ≥ 160mmHg(millimeter of mercury) or ≤ 100mmHg(millimeter of mercury) , Diastolic blood pressure ≥ 95mmHg(millimeter of mercury) or ≤ 60mmHg(millimeter of mercury) at the time of screening
  • History of drug abuse or a positive reaction for drug abuse in the urine at the time of screening
  • Taking medicines that are known to significantly induce or inhibit drug metabolizing enzymes, including barbiturates, within 30 days of the first dosing
  • Those who experience photoallergy or phototoxicity during treatment with fibrates or ketoprofen
  • Taking ETC(Ethical Drug), oriental medicine within 2 weeks and OTC(Over-the-counter Drug), vitamin within 10 days before the first dosing
  • Taking the medication involved in other clinical trials within 3 months before the first dosing
  • Whole blood donation with 2 months, component blood donation or blood transfusion within 1 month before the first dosing
  • Alcohol > 21 units/week (1unit=10g of pure alcohol), continuously within 6 month before the first dosing or Who can not stop drinking alcohol during the clinical trial
  • Smoker(> 10 cigarettes/day) for the last 3 months or who can not stop smoking during the clinical trial
  • Consumption of food containing grapefruit within 48 hours before first dosing and who can not stop consumption it until EOS(End of study)
  • Consumption of food containing caffeine(e.g. coffee, green tea etc.) within 24 hours before first dosing and who can not stop consumption it until discharge
  • Not using a reliable contraception or planning a pregnancy during the clinical trial
  • Unsuitable Conditions including laboratory result by investigator's judgement

Trial design

60 participants in 2 patient groups

A
Experimental group
Description:
Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions. Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.
Treatment:
Drug: Test drug(CKD-337)
Drug: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)
B
Experimental group
Description:
Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions. Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.
Treatment:
Drug: Test drug(CKD-337)
Drug: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems